|Brand name(s), other common name(s)||Zelboraf®|
|Drug type||Kinase inhibitor|
|How the drug is given||By mouth|
Indications and Usage
Vemurafenib (Zelboraf®) is FDA approved for the treatment of patients with Erdheim-Chester Disease (ECD) with BRAF V600 mutation.
Side effects needing medical attention
Joint pain, a flat or raised red bump on the skin (rash maculo-papular), hair loss (alopecia), fatigue, electrocardiogram QT interval prolonged, and benign, sometimes multiple, tumors caused by viruses (skin papilloma).